Eldecalcitol for the treatment of osteoporosis

References

• No authors listedConsensus development conference: diagnosis, prophylaxis, and treatment of osteoporosisAm J Med19939466466508506892
   PubMed Web of Science ®Google Scholar
• CauleyJAThompsonDEEnsrudKCScottJCBlackDRisk of mortality following clinical fracturesOsteoporos Int200011755656111069188
   PubMed Web of Science ®Google Scholar
• BianchiMLOrsiniMRSaraifogerSOrtolaniSRadaelliGBettiSQuality of life in post-menopausal osteoporosisHealth Qual Life Outcomes200537816321148
   PubMedGoogle Scholar
• HolickMFVitamin D deficiencyN Engl J Med2007357326628117634462
   PubMed Web of Science ®Google Scholar
• PeacockMCalcium metabolism in health and diseaseClin J Am Soc Nephrol20105Suppl 1S23S3020089499
   PubMed Web of Science ®Google Scholar
• KennelKADrakeMTHurleyDLVitamin D deficiency in adults: when to test and how to treatMayo Clin Proc201085875275720675513
   PubMed Web of Science ®Google Scholar
• LipsPBouillonRvan SchoorNMReducing fracture risk with calcium and vitamin DClin Endocrinol (Oxf)201073327728520796001
   PubMed Web of Science ®Google Scholar
• JanssenHCSamsonMMVerhaarHJVitamin D deficiency, muscle function, and falls in elderly peopleAm J Clin Nutr200275461161511916748
   PubMed Web of Science ®Google Scholar
• HolickMFResurrection of vitamin D deficiency and ricketsJ Clin Invest200611682062207216886050
   PubMed Web of Science ®Google Scholar
• LipsPVitamin D physiologyProg Biophys Mol Biol20069214816563471
   PubMed Web of Science ®Google Scholar
• PapadimitropoulosEWellsGSheaBOsteoporosis Methodology Group and The Osteoporosis Research Advisory GroupMeta-analyses of therapies for postmenopausal osteoporosis. VIII: Meta-analysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal womenEndocr Rev200223456056912202471
   PubMed Web of Science ®Google Scholar
• O’DonnellSMoherDThomasKHanleyDACranneyASystematic review of the benefits and harms of calcitriol and alfacalcidol for fractures and fallsJ Bone Miner Metab200826653154218979152
   PubMed Web of Science ®Google Scholar
• Bischoff-FerrariHADawson-HughesBStaehelinHBFall prevention with supplemental and active forms of vitamin D: a metaanalysis of randomised controlled trialsBMJ2009339b369219797342
   PubMed Web of Science ®Google Scholar
• SanfordMMcCormackPLEldecalcitol: a review of its use in the treatment of osteoporosisDrugs201171131755177021902297
   PubMed Web of Science ®Google Scholar
• MatsumotoTEndoIEldecalcitol for the treatment of osteoporosisDrugs Today (Barc)201248318919622462038
   PubMed Web of Science ®Google Scholar
• DeLucaHFOverview of general physiologic features and functions of vitamin DAm J Clin Nutr200480Suppl 61689S1696S15585789
   PubMed Web of Science ®Google Scholar
• HolickMFSunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular diseaseAm J Clin Nutr200480Suppl 61678S1688S15585788
   PubMed Web of Science ®Google Scholar
• HausslerMRWhitfieldGKKanekoIMolecular mechanisms of vitamin D actionCalcif Tissue Int2013922779822782502
   PubMed Web of Science ®Google Scholar
• AdamsJSHewisonMUpdate in vitamin DJ Clin Endocrinol Metab201095247147820133466
   PubMed Web of Science ®Google Scholar
• HolickMFBinkleyNCBischoff-FerrariHAGuidelines for preventing and treating vitamin D deficiency and insufficiency revisitedJ Clin Endocrinol Metab20129741153115822442274
   PubMed Web of Science ®Google Scholar
• HolickMFSirisESBinkleyNPrevalence of Vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapyJ Clin Endocrinol Metab20059063215322415797954
   PubMed Web of Science ®Google Scholar
• LipsPHoskingDLippunerKThe prevalence of vitamin D inadequacy amongst women with osteoporosis: an international epidemiological investigationJ Intern Med2006260324525416918822
   PubMed Web of Science ®Google Scholar
• MowéMHaugEBøhmerTLow serum calcidiol concentration in older adults with reduced muscular functionJ Am Geriatr Soc19994722202269988294
   PubMed Web of Science ®Google Scholar
• SteinMSWarkJDSchererSCFalls relate to vitamin D and parathyroid hormone in an Australian nursing home and hostelJ Am Geriatr Soc199947101195120110522952
   PubMed Web of Science ®Google Scholar
• Bischoff-FerrariHADawson-HughesBWillettWCEffect of Vitamin D on falls: a meta-analysisJAMA2004291161999200615113819
   PubMed Web of Science ®Google Scholar
• OrimoHNakamuraTHosoiTJapanese 2011 guidelines for prevention and treatment of osteoporosis – executive summaryArch Osteoporos201271–232023203733
   PubMedGoogle Scholar
• ShikariMKushidaKYamazakiKNagaiTInoueTOrimoHEffects of 2 years’ treatment of osteoporosis with 1 alpha-hydroxy vitamin D3 on bone mineral density and incidence of fracture: a placebo-controlled, double-blind prospective studyEndocr J19964322112209026268
   PubMed Web of Science ®Google Scholar
• GallagherJCFowlerSEDetterJRShermanSSCombination treatment with estrogen and calcitriol in the prevention of age-related bone lossJ Clin Endocrinol Metab20018683618362811502787
   PubMed Web of Science ®Google Scholar
• RingeJDSchachtEPotential of alfacalcidol for reducing increased risk of falls and fracturesRheumatol Int200929101177118519159932
   PubMed Web of Science ®Google Scholar
• DukasLBischoffHALindpaintnerLSAlfacalcidol reduces the number of fallers in a community-dwelling elderly population with a minimum calcium intake of more than 500 mg dailyJ Am Geriatr Soc200452223023614728632
   PubMed Web of Science ®Google Scholar
• RichyFSchachtEBruyereOEthgenOGourlayMReginsterJYVitamin D analogs versus native vitamin D in preventing bone loss and osteoporosis-related fractures: a comparative meta-analysisCalcif Tissue Int200576317618615692726
   PubMed Web of Science ®Google Scholar
• OkanoTTsugawaNMasudaSRegulatory activities of 2 beta-(3-hydroxypropoxy)-1 alpha, 25-dihydroxyvitamin D3, a novel synthetic vitamin D3 derivative, on calcium metabolismBiochem Biophys Res Commun19891633144414492551289
   PubMed Web of Science ®Google Scholar
• TakahashiNMechanism of inhibitory action of Eldecalcitol, an active vitamin D analog, on bone resorption in vivoJ Steroid Biochem Mol Biol201313617117423220095
   PubMed Web of Science ®Google Scholar
• HatakeyamaSNagashimaSImaiNSynthesis and biological evaluation of a 3-positon epimer of 1alpha,25-dihydroxy-2beta-(3-hydroxypropoxy)vitamin D3 (ED-71)J Steroid Biochem Mol Biol20071033–522222617207991
   PubMed Web of Science ®Google Scholar
• HaradaSTakedaSUnoATakahashiFSaitoHEldecalcitol is less effective in suppressing parathyroid hormone compared to calcitriol in vivoJ Steroid Biochem Mol Biol20101211–228128320398764
   PubMed Web of Science ®Google Scholar
• UchiyamaYHiguchiYTakedaSED-71, a vitamin D analog, is a more potent inhibitor of bone resorption than alfacalcidol in an estrogen-deficient rat model of osteoporosisBone200230458258811934649
   PubMed Web of Science ®Google Scholar
• TanakaYNakamuraTNishidaSEffects of a synthetic vitamin D analog, ED-71, on bone dynamics and strength in cancellous and cortical bone in prednisolone-treated ratsJ Bone Miner Res19961133253368852943
   PubMed Web of Science ®Google Scholar
• ShiraishiAHigashiSOhkawaHThe advantage of alfacalcidol over vitamin D in the treatment of osteoporosisCalcif Tissue Int199965431131610485984
   PubMed Web of Science ®Google Scholar
• HaradaSMizoguchiTKobayashiYDaily administration of eldecalcitol (ED-71), an active vitamin D analog, increases bone mineral density by suppressing RANKL expression in mouse trabecular boneJ Bone Miner Res201227246147322052469
   PubMed Web of Science ®Google Scholar
• de FreitasPHHasegawaTTakedaSEldecalcitol, a second-generation vitamin D analog, drives bone minimodeling and reduces osteoclastic number in trabecular bone of ovariectomized ratsBone201149333534221664310
   PubMed Web of Science ®Google Scholar
• SaitoHTakedaSAmizukaNEldecalcitol and calcitriol stimulates ‘bone minimodeling,’ focal bone formation without prior bone resorption, in rat trabecular boneJ Steroid Biochem Mol Biol201313617818223069645
   PubMed Web of Science ®Google Scholar
• SakaiSEndoKTakedaSMiharaMShiraishiACombination therapy with eldecalcitol and alendronate has therapeutic advantages over monotherapy by improving bone strengthBone20125051054106322366400
   PubMed Web of Science ®Google Scholar
• SugimotoMFutakiNHaradaMKakuSEffects of combined treatment with eldecalcitol and alendronate on bone mass, mechanical properties, and bone histomorphometry in ovariectomized rats: a comparison with alfacalcidol and alendronateBone201352118118823041510
   PubMed Web of Science ®Google Scholar
• TakedaSSakaiSShiraishiAKoikeNMiharaMEndoKCombination treatment with eldecalcitol (ED-71) and raloxifene improves bone mechanical strength by suppressing bone turnover and increasing bone mineral density in ovariectomized ratsBone201353116717323232307
   PubMed Web of Science ®Google Scholar
• AbeMTsujiNTakahashiFTanigawaYOverview of the clinical pharmacokinetics of eldecalcitol, a new active vitamin D3 derivativeJpn Pharmacol Ther2011393261274
   Google Scholar
• MatsumotoTTakanoTYamakidoSTakahashiFTsujiNComparison of the effects of eldecalcitol and alfacalcidol on bone and calcium metabolismJ Steroid Biochem Mol Biol20101211–226126420298784
   PubMed Web of Science ®Google Scholar
• MatsumotoTKuboderaNThe ED-71 Study Group1α,25-Dihydroxy-2β-(3-hydroxypropoxy) vitamin D3(ED-71): a promising candidate for the treatment of osteoporosisProceedings of the 11th Workshop on Vitamin D2000985992
   Google Scholar
• KuboderaNTsujiNUchiyamaYEndoKA new active vitamin D analog, ED-71, causes increase in bone mass with preferential effects on bone in osteoporotic patientsJ Cell Biochem200388228628912520528
   PubMed Web of Science ®Google Scholar
• MatsumotoTMikiTHaginoHA new active vitamin D, ED-71, increases bone mass in osteoporotic patients under vitamin D supplementation: a randomized, double-blind, placebo-controlled clinical trialJ Clin Endocrinol Metab20059095031503615972580
   PubMed Web of Science ®Google Scholar
• MatsumotoTKuboderaNED-71, a new active vitamin D3, increases bone mineral density regardless of serum 25(OH)D levels in osteoporotic subjectsJ Steroid Biochem Mol Biol20071033–558458617298881
   PubMed Web of Science ®Google Scholar
• MatsumotoTItoMHayashiYA new active vitamin D3 analog, eldecalcitol, prevents the risk of osteoporotic fractures – a randomized, active comparator, double-blind studyBone201149460561221784190
   PubMed Web of Science ®Google Scholar
• NishizawaYOhtaHMiuraMGuidelines for the use of bone metabolic markers in the diagnosis and treatment of osteoporosis (2012 edition)J Bone Miner Metab201331111523143508
   PubMed Web of Science ®Google Scholar
• HaginoHTakanoTFukunagaMShirakiMNakamuraTMatsumotoTEldecalcitol reduces the risk of severe vertebral fractures and improves the health-related quality of life in patients with osteoporosisJ Bone Miner Metab201331218318923129180
   PubMed Web of Science ®Google Scholar
• KanisJAOdenAJohanssonHBorgströmFStrömOMcCloskeyEFRAX and its applications to clinical practiceBone200944573474319195497
   PubMed Web of Science ®Google Scholar
• NakamuraTTakanoTFukunagaMShirakiMMatsumotoTEldecalcitol is more effective for the prevention of osteoporotic fractures than alfacalcidolJ Bone Miner Metab201331441742223575909
   PubMed Web of Science ®Google Scholar
• ShirakiMSaitoHMatsumotoTEldecalcitol normalizes bone turnover markers regardless of their pre-treatment levelsCurr Med Res Opin20122891547155222794117
   PubMed Web of Science ®Google Scholar
• ItoMNakamuraTFukunagaMShirakiMMatsumotoTEffect of eldecalcitol, an active vitamin D analog, on hip structure and biomechanical properties: 3D assessment by clinical CTBone201149332833421605716
   PubMed Web of Science ®Google Scholar
• RingeJDFarahmandPSchachtERozehnalASuperiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial)Rheumatol Int200727542543417216477
   PubMed Web of Science ®Google Scholar
• OrimoHNakamuraTFukunagaMA-TOP (Adequate Treatment of Osteoporosis) research groupEffects of alendronate plus alfacalcidol in osteoporosis patients with a high risk of fracture: the Japanese Osteoporosis Intervention Trial (JOINT) – 02Curr Med Res Opin20112761273128421554143
   PubMed Web of Science ®Google Scholar
• TakasuHSugitaAUchiyamaYc-Fos protein as a target of anti-osteoclastogenic action of vitamin D, and synthesis of new analogsJ Clin Invest2006116252853516424941
   PubMed Web of Science ®Google Scholar
• AtkinsGJKostakisPPanBRANKL expression is related to the differentiation state of human osteoblastsJ Bone Miner Res20031861088109812817763
   PubMed Web of Science ®Google Scholar
• KikutaJKawamuraSOkijiFSphingosine-1-phosphate-mediated osteoclast precursor monocyte migration is a critical point of control in antibone-resorptive action of active vitamin DProc Natl Acad Sci U S A2013110177009701323569273
   PubMed Web of Science ®Google Scholar